Kostenuik, Paul J.

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis, and regulation of bone mass and calcium metabolism.

Li, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences

Bone Metabolism and DiseasesOsteomyelitis and Bone Disorders Research

Cited by 1,119

Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease

Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 824

Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.

Min, H., Morony, S., Sarosi, I., Dunstan, C. R., Capparelli, C., Scully, S., Van, G., Kaufman, S., Kostenuik, P. J., Lacey, D. L., et al. (2000) · The Journal of Experimental Medicine

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 550

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.

KOSTENUIK, P. (2005) · Current Opinion in Pharmacology

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 281

Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr (−/−) Mice

Morony, S., Tintut, Y., Zhang, Z., Cattley, R. C., Van, G., Dwyer, D., Stolina, M., Kostenuik, P. J., & Demer, L. L. (2008) · Circulation

Atherosclerosis and Cardiovascular DiseasesBone Metabolism and Diseases

Cited by 258

Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells

Streicher, C., Heyny, A., Andrukhova, O., Haigl, B., Slavic, S., Schüler, C., Kollmann, K., Kantner, I., Sexl, V., Kleiter, M., et al. (2017) · Scientific Reports

Bone Metabolism and DiseasesEstrogen and related hormone effects

Cited by 251

OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats.

Kostenuik, P. J., Capparelli, C., Morony, S., Adamu, S., Shimamoto, G., Shen, V., Lacey, D. L., & Dunstan, C. R. (2001) · Endocrinology

Bone health and osteoporosis researchBone Metabolism and Diseases

Cited by 140

Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis.

Redlich, K., Görtz, B., Hayer, S., Zwerina, J., Doerr, N., Kostenuik, P., Bergmeister, H., Kollias, G., Steiner, G., Smolen, J. S., et al. (2004) · The American Journal of Pathology

Rheumatoid Arthritis Research and TherapiesBone Metabolism and Diseases

Cited by 134

Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and to insulin-like growth factor-I.

Kostenuik, P. J., Harris, J., Halloran, B. P., Turner, R. T., Morey-Holton, E. R., & Bikle, D. D. (1999) · Journal of Bone and Mineral Research

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 119

Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.

Capparelli, C., Morony, S., Warmington, K., Adamu, S., Lacey, D., Dunstan, C. R., Stouch, B., Martin, S., & Kostenuik, P. J. (2003) · Journal of Bone and Mineral Research

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 103

Adenoviral Delivery of Osteoprotegerin Ameliorates Bone Resorption in a Mouse Ovariectomy Model of Osteoporosis

Bolon, B., Carter, C., Daris, M., Morony, S., Capparelli, C., Hsieh, A., Mao, M., Kostenuik, P., Dunstan, C. R., Lacey, D. L., et al. (2001) · Molecular Therapy

Bone Metabolism and DiseasesVirus-based gene therapy research

Cited by 100

RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis.

Stolina, M., Adamu, S., Ominsky, M., Dwyer, D., Asuncion, F., Geng, Z., Middleton, S., Brown, H., Pretorius, J., Schett, G., et al. (2005) · Journal of Bone and Mineral Research

Bone Metabolism and DiseasesRheumatoid Arthritis Research and Therapies

Cited by 99

The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.

Morony, S., Warmington, K., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M., Tan, H. L., Capparelli, C., Starnes, C., Weimann, B., et al. (2005) · Endocrinology

Bone Metabolism and DiseasesBone health and treatments

Cited by 97

RANKL Inhibition: A Novel Strategy to Decrease Femoral Head Deformity After Ischemic Osteonecrosis

Kim, H. K., Morgan-Bagley, S., & Kostenuik, P. (2006) · Journal of Bone and Mineral Research

Bone and Joint DiseasesBone Metabolism and Diseases

Cited by 89

Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.

Kostenuik, P. J., Bolon, B., Morony, S., Daris, M., Geng, Z., Carter, C., & Sheng, J. (2004) · Bone

Bone Metabolism and DiseasesVirus-based gene therapy research

Cited by 82

Osteoprotegerin is an effective countermeasure for spaceflight-induced bone loss in mice

Lloyd, S. A., Morony, S. E., Ferguson, V. L., Simske, S. J., Stodieck, L. S., Warmington, K. S., Livingston, E. W., Lacey, D. L., Kostenuik, P. J., & Bateman, T. A. (2015) · Bone

Spaceflight effects on biologyBone Metabolism and Diseases

Cited by 68

Continuous RANKL Inhibition in Osteoprotegerin Transgenic Mice and Rats Suppresses Bone Resorption without Impairing Lymphorganogenesis or Functional Immune Responses

Stolina, M., Dwyer, D., Ominsky, M. S., Corbin, T., Van, G., Bolon, B., Sarosi, I., McCabe, J., Zack, D. J., & Kostenuik, P. (2007) · The Journal of Immunology

Bone Metabolism and DiseasesRheumatoid Arthritis Research and Therapies

Cited by 63

The effects of osteoprotegerin on the mechanical properties of rat bone.

Ross, A. B., Bateman, T. A., Kostenuik, P. J., Ferguson, V. L., Lacey, D. L., Dunstan, C. R., & Simske, S. J. (2001) · Journal of Materials Science: Materials in Medicine

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 39

Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone.

Kostenuik, P. J., Singh, G., Suyama, K. L., & Orr, F. W. (1992) · Clinical & Experimental Metastasis

Bone Metabolism and DiseasesBone health and treatments

Cited by 34

A quantitative model for spontaneous bone metastasis: evidence for a mitogenic effect of bone on Walker 256 cancer cells.

Kostenuik, P. J., Singh, G., Suyama, K. L., & Orr, F. W. (1992) · Clinical & Experimental Metastasis

Bone health and treatmentsCancer Cells and Metastasis

Cited by 29

197 POSTER Denosumab is a selective inhibitor of human receptor activator of NF-kB ligand that blocks osteoclast formation in vitro and in vivo

Elliott, R., Kostenuik, P., Chen, C., Kelley, M., Hawkins, N., Housman, J., McCabe, S., Mukku, V., Sullivan, J., & Dougall, W. (2006) · European Journal of Cancer Supplements

Head and Neck Cancer StudiesBone health and treatments

Cited by 14